Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. mlee42@partners.org.
Min Jung
MJ
Lee
Paige
P
Wickner
Laura
L
Fanning
Robert
R
Schlossman
Paul
P
Richardson
Jacob
J
Laubach
Maria
M
Castells
D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity / Q000209:etiology* / Q000628:therapy*; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology* / Q000628:therapy*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide
allergy; desensitization; lenalidomide; multiple myeloma; myeloma therapy